Trevena’s (TRVN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Trevena (NASDAQ:TRVN) in a report published on Thursday morning, MarketBeat Ratings reports. The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Trevena’s Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.

Separately, StockNews.com began coverage on shares of Trevena in a research report on Monday, November 11th. They issued a “sell” rating on the stock.

Trevena Trading Down 0.6 %

NASDAQ TRVN opened at $1.68 on Thursday. The firm’s fifty day moving average price is $3.05 and its two-hundred day moving average price is $5.61. Trevena has a 1 year low of $1.13 and a 1 year high of $19.23. The firm has a market capitalization of $1.45 million, a P/E ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million for the quarter. On average, research analysts anticipate that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.